ClinicalTrials.gg

Program

afabicin

Also written as “Debio 1450”, “Afabicin Oral” and “Afabicin IV”.

Its studies are mostly in Bacterial Infections · Renal Insufficiency, led by Debiopharm.

Furthest: phase 2, since Apr 22, 20157 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Debiopharm71 open or runningphase 2since Apr 22, 2015Jun 10, 2014Dec 2027phase 1 · NCT07758608

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 10, 2014First study: phase 1 study in Bacterial InfectionsFirst studyNCT02162199 · 48 enrolled · United States
  2. Aug 8, 2014Phase 1 study in Bacterial InfectionsNCT02214433 · 70 enrolled · United States
  3. Apr 22, 2015Phase 2 study in Bacterial InfectionsNCT02426918 · 330 enrolled · United States
  4. Mar 29, 2016Phase 1 study in Bone Diseases, InfectiousNCT02726438 · 17 enrolled · United States
  5. Jul 4, 2017Phase 1 study in Healthy ParticipantsNCT03209648 · 20 enrolled · United Kingdom
  6. Oct 26, 2018Phase 2 study in Bone or Joint InfectionNCT03723551 · 67 enrolled · Georgia, South Africa, Ukraine
  7. Aug 6, 2026Phase 1 study in Renal InsufficiencyNCT07758608 · 60 planned · Germany

Ahead

  1. Dec 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07758608

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Enoyl-[acyl-carrier-protein] reductase (FabI) inhibitor”ChEMBL 37, by rule

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07758608Renal Insufficiency · Germany1RecruitingDec 202760
NCT03723551Bone or Joint Infection · Georgia, South Africa, Ukraine2TerminatedApr 23, 202567
NCT03209648Healthy Participants · United Kingdom1CompletedAug 23, 201720
NCT02726438Bone Diseases, Infectious · United States1CompletedJun 201717
NCT02426918Bacterial Infections · United States2CompletedAug 2016330
NCT02214433Bacterial Infections · United States1CompletedFeb 201570
NCT02162199Bacterial Infections · United States1CompletedOct 201448

How it is read

Names in the registry

  • “Debio 1450”, 3 entries
  • “Afabicin Oral”, 1 entry
  • “Afabicin IV”, 1 entry
  • “Afabicin”, 1 entry
  • “Debio 1450 IV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.